Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508) combined with paclitaxel in patients with refractory metastatic breast cancer.
Ferrario C, Mackey J, Gelmon KA, Levasseur N, Sorensen PH, Oo HZ, Negri GL, Tse VWL, Spencer SE, Cheng G, Morin GB, Del Rincon S, Cotechini T, Gonçalves C, Hindmarch CCT, Miller WH, Amiri M, Basiri T, Villareal-Corpuz V, Sperry S, Gregorczyk K, Spera G, Sonenberg N, Pollak M.
Ferrario C, et al. Among authors: miller wh.
Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-0841. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39576211